Foamix pharmaceuticals ltd. (FOMX)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Jun'16Jun'15Jun'14
REVENUES (Note 13b)

443

1,168

2,033

2,997

3,595

3,778

3,814

3,648

3,669

0

0

0

0

0

0

COST OF REVENUES

-

-

-

-

-

-

-

-

-

0

-

-

0

0

0

GROSS PROFIT

-

-

-

-

-

-

-

-

-

0

-

-

0

0

0

OPERATING EXPENSES:
Research and development

51,202

47,521

48,211

52,497

64,474

68,188

70,831

67,929

57,779

0

0

0

0

0

0

Selling, general and administrative

45,114

26,888

19,450

15,556

14,013

12,304

11,928

12,470

11,491

0

0

0

0

0

0

TOTAL OPERATING EXPENSES

96,316

74,409

67,661

68,053

78,487

80,492

82,759

80,399

69,270

0

0

0

0

0

0

OPERATING LOSS

-95,873

-73,241

-65,628

-65,056

-74,892

-76,716

-78,958

-76,764

-65,614

0

0

0

0

0

0

FINANCE INCOME (Note 13c)

1,672

1,422

1,503

1,416

985

759

942

950

1,134

0

0

0

0

0

0

LOSS BEFORE INCOME TAX

-95,354

-71,863

-64,169

-63,684

-73,951

-76,028

-78,087

-75,885

-64,551

0

0

0

0

0

-

INCOME TAX (Note 12)

-176

-427

-414

-294

212

1,418

1,462

1,423

1,164

0

0

0

0

0

0

NET LOSS FOR THE YEAR

-95,178

-71,436

-63,755

-63,390

-74,163

-77,446

-79,549

-77,308

-65,715

0

0

0

0

0

0

LOSS PER SHARE BASIC AND DILUTED

0.62

0.41

0.35

0.28

0.17

0.38

0.46

0.69

0.46

0.47

0.44

0.39

0.27

0.18

0.30

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS

64,388

55,984

54,426

54,370

56,124

40,873

40,102

37,541

37,465

37,431

37,420

37,188

30,661

25,917

11,408